Please assess the completion status of the following clinical trial:

Trial Title: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed, CD30-positive mature T-cell lymphomas~* Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~Exclusion Criteria:~* History of another primary invasive malignancy that has not been in remission for at least 3 years~* Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas or mycosis fungoides~* History of progressive multifocal leukoencephalopathy (PML)~* Cerebral/meningeal disease related to the underlying malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHOP (Type: ACTIVE_COMPARATOR): cyclophosphamide, doxorubicin, vincristine, and prednisone
- A+CHP (Type: EXPERIMENTAL): brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).